オハイオにおける子宮内膜がんの臨床試験
オハイオ内の拠点で、子宮内膜がんに関する50件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- OhioHealth O'Bleness Hospital, Athens
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- 他39件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
- Cleveland Clinic Foundation, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1相
18歳以上 · 女性 · 2026/10/02更新 · NCT05950464The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- OhioHealth O'Bleness Hospital, Athens
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Aultman Health Foundation, Canton
- 他19件
被験者募集中第3相
18歳以上 · 女性 · 2026/10/02更新 · NCT07198074A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Cleveland Clinic - Oncology Department, Cleveland
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 06, Maumee
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07814248Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Cleveland Clinic, Cleveland
被験者募集中観察研究
18歳以上 · 女性 · 2026/09/29更新 · NCT05051722Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Miami Valley Hospital South, Centerville
- Geauga Hospital, Chardon
- 他8件
被験者募集中第2相
18歳以上 · 女性 · 2026/09/28更新 · NCT05112601Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05867251DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
被験者募集中観察研究
18歳〜130歳 · 全性別 · 2026/09/25更新 · NCT07124000Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- The Ohio State University Wexner Medical Center, Columbus
被験者募集中第1/2相
18歳以上 · 女性 · 2026/09/25更新 · NCT03564340A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- The Ohio State University Wexner Medical Center, Columbus
被験者募集中第1/2相
18歳以上 · 女性 · 2026/09/24更新 · NCT04590326Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Geauga Hospital, Chardon
- Case Western Reserve University, Cleveland
- 他4件
被験者募集中第2相
18歳以上 · 女性 · 2026/09/24更新 · NCT05640999Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Cincinnati
- Research Site, Columbus
被験者募集中第2相
18歳〜130歳 · 全性別 · 2026/09/23更新 · NCT05489211A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Miami Valley Hospital South ( Site 6014), Centerville
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007), Columbus
- Kettering Health Main Campus-Kettering Health Cancer Center ( Site 5001), Kettering
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT06952504A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- UH Cleveland Medical Center, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07109726A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Miami Valley Hospital South, Centerville
- Ohio State University, Hilliard
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT06340568A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- GSK Investigational Site, Canton
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07213609ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cleveland Clinic, Cleveland
- Toledo Clinic Cancer Center, Toledo
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- University of Cincinnati Medical Center, Cincinnati
被験者募集中第3相
18歳以上 · 女性 · 2026/09/09更新 · NCT07166094A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The Ohio State University (OSU) Wexner Medical Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06400472DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Cincinnati
- Research Site, Columbus
被験者募集中第3相
18歳以上 · 女性 · 2026/09/03更新 · NCT06989112Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- The Ohio State University, Columbus
被験者募集中第1相
15歳以上 · 全性別 · 2026/08/25更新 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Cleveland Clinic Taussig Cancer Institute, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06774963Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Columbus
被験者募集中第1/2相
18歳〜130歳 · 全性別 · 2026/08/21更新 · NCT05797168A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Miami Valley Hospital South, Centerville
- University of Cincinnati Cancer Center, Cincinnati
- Ohio State University, Hilliard
被験者募集中第2相
18歳以上 · 女性 · 2026/08/21更新 · NCT05548296A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Maumee
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- Ohio State University Wexner Medical Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07470853FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
- Cleveland Clinic, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- University Hospital - Cleveland Medical Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/05更新 · NCT07444814Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Oncology Hematology Care Primary, Cincinnati
- Taylor Cancer Research Center, Maumee
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Cincinnati
- Research Site, Cleveland
- Research Site, Cleveland
- 他4件
被験者募集中第3相
18歳以上 · 女性 · 2026/07/29更新 · NCT07044336Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
- University of Cincinnati Physicians Group, LLC, Cincinnati
被験者募集中第3相
18歳以上 · 女性 · 2026/07/28更新 · NCT07022483A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05208762Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 304, Centerville
被験者募集中第2相
18歳以上 · 女性 · 2026/07/16更新 · NCT06906341First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- UH Cleveland Medical Center, Cleveland
- Stefanie Spielman Comprehensive Breast Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/07更新 · NCT05768139Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。